Why America's AI Boom Isn't an Industrial Boom

The United States is witnessing a significant increase in AI investment, with hyperscalers' expenditure soaring to $750 billion in 2025 from $15 billion in 2005. However, this surge in AI funding has not translated into the anticipated industrial revolution. Despite the substantial spending, the share of productive investment in the U.S. GDP has remained stagnant.

Productive investment refers to spending on assets like factories, equipment, infrastructure, and intellectual property, which form the foundation for future productivity and competitiveness.

China, on the other hand, is rapidly adding around $4.4 trillion in net productive assets each year, a figure that is roughly four times the corresponding amount in the United States. This disparity highlights the need for the U.S. to invest more in manufacturing, an estimated $2 trillion, or around 6% of its GDP, to address its import dependencies.

However, the pace of industrial investment in the U.S. has slowed down. In 2025, investment in factory structures fell by 6%, whereas investment in general industrial equipment remained static. Moreover, there has been a modest increase in machinery and equipment investment in the first quarter of the current year. The resumption of reshoring efforts that began in 2022 has also plateaued, with recent announcements likely to take time to materialize into actual construction and development.

A major obstacle to launching a U.S. industrial renaissance is the high cost of production in America. Compared to competitive locations, the cost of building products such as semiconductors and pharmaceuticals in the U.S. is approximately 40% and 60% higher, respectively. The cost of developing a new antibody medicine is even higher, being about 2.7 times more expensive than in China.

Two primary factors contribute to this cost gap: higher and slower capital expenditure delivery and significantly elevated labor costs. U.S. construction costs are about twice as high as in Asia, and project completion times can be twice as long, with recent nuclear projects taking up to a decade to finish compared to six years in China.

Additionally, labor costs in the U.S. are two to five times higher than in China or Taiwan, a factor that used to be compensated by productivity differences. However, these differences have largely disappeared in like-for-like industrial settings.

To bridge these gaps, companies seeking to manufacture domestically could consider adopting modular, off-site methods that can cut project timelines by half and capital costs by 10 to 20%. Additionally, deploying technology, collaborative contracting, and other measures can help lower construction costs. If cost competitiveness is not feasible, companies can compete based on service quality, brand, customer proximity, and innovation.

Complex drug therapies, for instance, command premium margins and a decade or more of effective commercial exclusivity, enabling them to sustain premium prices through performance and trust.